课题基金 / 基金详情

Cancer Immunotherapy Winter School (CIWS)

Cancer Immunotherapy Winter School (CIWS)
癌症免疫治疗冬季学校(CIWS)
批准号:
10391811
负责人:
Catherine M. Bollard
金额:
$3.0万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-01-01 至 2022-12-31

项目摘要

项目成果

Catherine M. Bollard的其他基金

相似基金

相关文献

中文摘要
翻译
4.0项目概要/摘要 成立于1984年的癌症免疫治疗学会(SITC)是世界领先的会员驱动的 该组织专门致力于通过推进科学和 癌症免疫治疗的应用。国贸中心的使命是通过以下方式改善癌症患者的治疗结果: 推进癌症免疫学和免疫治疗的科学,发展和应用,通过我们的 互动/整合、创新、翻译和在该领域的领导力的核心价值观。的最前沿 SITC的教育费用是癌症免疫疗法冬季学校(CIWS)方案。2022计划在 德克萨斯州奥斯汀将专注于提供一个旨在使基础,临床或转化科学家和 来自整个癌症护理团队的临床医生,包括来自不同和代表性不足的群体的临床医生, 生物医学科学,推进肿瘤免疫学的科学发现和临床应用, 癌症免疫疗法这个全面的,为期五天的认证CME-/CNE-/CPE-/MOC认证计划将 提供对肿瘤免疫学,癌症免疫治疗和 在外地发展。有51个主题,包括基础免疫学,临床试验设计, 联合治疗,生物标志物整合和数据分析,与会者有许多会议类型(所有- 与会者、分组讨论、研究/临床跟踪),通过以下方式最大限度地提高学习机会和学习风格 选择与其教育需求最相关的课程。这使得许多机会, 与会者和专家之间的个性化互动。与会者通过小组会议和 网络圆桌会议,将扩大他们的专业网络,与教师发展新的关系, 其他思想领袖。这些实践课程将提供宝贵的网络和指导 机会,并从自己的经验中提出问题。由全球各地的专家设计和批准, 医疗保健范围-临床医生、护士、药剂师、急诊医生和患者 倡导者-确定所有观点都被纳入。对于现场课程的参与者, 材料可在程序后,并将作为他们的学习加强,并允许 参加他们无法参加的其他并行会议。材料在六个月后向公众提供 象征性收费SITC,项目组织者和教师证明CIWS对所有希望参加的人开放 这是一个安全和尊重的学习环境,没有任何形式的歧视和骚扰。低 注册率、旅行奖励、符合ADA的设施和集中的位置确保了障碍 而不是阻碍医生的知识和这些革命性治疗的最终使用。SITC是 独特的准备举行这一总理,教育选择所有医疗保健专业人员和每一种类型的 勒纳NIH对该计划的支持将允许继续教育和专业发展, 整个癌症护理团队,除了与同行和领导者在该领域的网络机会。
英文摘要
4.0 PROJECT SUMMARY/ABSTRACT Established in 1984, the Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. The mission of SITC is to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. At the forefront of SITC’s educational charge is the Cancer Immunotherapy Winter School (CIWS) program. The 2022 program in Austin, TX will focus on delivering a program designed to enable basic, clinical, or translational scientists and clinicians from the entire cancer care team including those from diverse and underrepresented groups in biomedical sciences, to advance scientific discoveries and clinical applications of tumor immunology and cancer immunotherapy. This comprehensive, five-day accredited CME-/CNE-/CPE-/MOC-certified program will provide a deep understanding of the core principles of tumor immunology, cancer immunotherapy and developing areas in the field. With 51 topics including foundational immunology, clinical trial design, combination therapies, biomarker integration and data analysis, attendees have a number of session types (all- attendee, breakout, research/clinical tracks) tailored to maximize learning opportunities and styles through selection of sessions most relevant to their educational needs. This allows for many opportunities of personalized interaction between attendees and experts. Attendees, through small group sessions and networking roundtables, will expand their professional network, developing new relationships with faculty and other thought leaders. These hands-on sessions will provide valuable networking and mentorship opportunities, and poise questions from their own experiences. Designed and approved by experts across the healthcare spectrum—clinical physicians, nurses, pharmacists, emergency physicians, and patient advocates—establishes that all points of view are incorporated. For attendees of in-person courses, enduring materials are available following the program and will serve as reinforcement of their learnings and allow access to other concurrent sessions they could not attend. Materials are available to the public six months later at a nominal fee. SITC, program organizers, and faculty certifies the CIWS is open to all who wish to attend and it is a safe and respectful learning environment free from all forms of discrimination and harassment. Low registration rates, travel awards, ADA-compliant facilities, and a centralized location ensures that obstacles do not stand in the way of physicians’ knowledge and eventual use of these revolutionary treatments. SITC is uniquely poised to hold this premier, educational option for all healthcare professionals and every type of learner. NIH support for this program will allow for continued educational and professional advancement for the entire cancer care team, in addition to networking opportunities with peers and leaders in the field.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NextGen - CRI
  • 批准号:
    10845777
  • 项目类别:
  • 资助金额:
    $73.84万
  • 财政年份:
    2022
  • 负责人:
    Catherine M. Bollard
  • 依托单位:
NextGen - CRI
  • 批准号:
    10627010
  • 项目类别:
  • 资助金额:
    $87.12万
  • 财政年份:
    2022
  • 负责人:
    Catherine M. Bollard
  • 依托单位:
Antigen Specific T Cells
  • 批准号:
    10197003
  • 项目类别:
  • 资助金额:
    $20.54万
  • 财政年份:
    2019
  • 负责人:
    Catherine M. Bollard
  • 依托单位:
Antigen Specific T Cells
  • 批准号:
    10671624
  • 项目类别:
  • 资助金额:
    $20.54万
  • 财政年份:
    2019
  • 负责人:
    Catherine M. Bollard
  • 依托单位:
海外基金